Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EU Project Targets Killer Viruses

01.03.2005


A new project targeting the increasing resistance of some viruses to drugs is being funded with the help of nine million euros under the Life Sciences, Genomics and Biotechnology for Health area of the EU’s Framework Programme.



The VIRGIL (Vigilance against Viral Resistance) project brings together experts from 55 organisations in 12 European countries to examine the problems being faced in treating certain diseases. Many of these problems have been caused by our heavy use of antivirals in treating viruses and this is resulting in a growing number of mutations in viruses that are becoming increasingly resistant to drugs.

VIRGIL draws on the experience of the top academic researchers within Europe as well as the pharmaceutical industry, clinicians and public health authorities to help save lives by overcoming the problems associated with viral drug resistance.


“Acute and chronic viral infections represent a major public health problem in Europe and are responsible for a major socio-economical burden”, says Howard Thomas, Professor of Medicine at Imperial College. “The development of new antiviral drugs and new diagnostic tools in the past decade has played a major role in the improvement of patient care and treatment of viral diseases to extend the quality and duration of human life. However, their increased use - and sometimes misuse - in medicine have brought about viral drug resistance. This has led to treatment failure and increased costs for health care and society.

“As there is no global programme to develop strategies for the surveillance and containment of viral resistance to antiviral agents, there is a clear need to implement a European program to optimise patients care and to minimise emergence and spread of antiviral drug resistance. The overall objective of the VIRGIL Network of Excellence is to set up the first-ever European Vigilance Network capable of addressing current and emerging antiviral drug resistance developments that will allow for the management of this critical problem in Europe.”

Initially, VIRGIL will be looking into drug resistance in the treatment of three major diseases - hepatitis B and C and influenza. This is because research shows that more than 520 million people around the world are chronically infected by hepatitis viruses (B or C). In addition, new strains of influenza cause up to 500,000 deaths every year worldwide. However, it is intended to broaden the scope later in the project.

VIRGIL is being built around seven ’research and technological platforms’ all centred around the patients. Two of them will test and monitor antiviral drug resistance in patients with the aim of improving and standardising the management of viral resistance on a global level. Other platforms will look to find the reasons for the increasing drug resistance with particular focus on patient-related factors. The project will also investigate how drugs, pharmacology, innovation and technology can be brought together to anticipate ways to beat drug resistance.

“Viral resistance is becoming a major health problem”, says Claire Horton, FP6UK’s National Contact Point for Life Sciences, Genomics and Biotechnology for Health. “The VIRGIL project complements a 30 million euro EU research investment into antimicrobial drug resistance over the past two years to address this growing problem.

Dave Sanders | alfa
Further information:
http://fp6uk.ost.gov.uk

More articles from Life Sciences:

nachricht What the world's tiniest 'monster truck' reveals
23.08.2017 | American Chemical Society

nachricht Treating arthritis with algae
23.08.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

What the world's tiniest 'monster truck' reveals

23.08.2017 | Life Sciences

Treating arthritis with algae

23.08.2017 | Life Sciences

Witnessing turbulent motion in the atmosphere of a distant star

23.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>